Milestone Reflects Surge in Demand for Lens-Based Refractive Solutions
Why are more patients and surgeons turning away from traditional laser-based refractive surgery? STAAR Surgical Company the global leader in phakic intraocular lenses (IOLs), has announced that it has sold more than 4 million Implantable Collamer® Lenses (ICLs) worldwide. This milestone underscores a significant shift in the vision correction industry, as patients and surgeons increasingly opt for lens-based solutions that preserve corneal integrity.
“Surpassing 4 million ICLs sold is a major milestone for STAAR,” said Deborah Andrews, Interim Co-Chief Executive Officer and Chief Financial Officer. “This achievement reflects not only the strength of our EVO ICL platform and its benefit to patients’ lives, but also the broader industry shift toward lens-based refractive correction.” This shift is driven by the growing preference for minimally invasive procedures that offer long-term vision correction without the need for corneal tissue removal. In the sections below, we delve into the implications of this milestone and what it means for the future of vision correction.
Key Insights at a Glance
- Global Preference: The 4 million ICL sales mark a significant global preference for lens-based refractive solutions.
- Minimally Invasive: EVO ICLs provide a minimally invasive alternative to traditional laser-based procedures.
- Regulatory Progress: Expanded regulatory indications have increased the addressable patient population for EVO ICLs.
- Long-Term Safety: Real-world evidence and clinical outcomes reinforce the safety and effectiveness of EVO ICLs.
Why Patients and Surgeons Prefer Lens-Based Solutions
The growing preference for lens-based refractive solutions is rooted in the minimally invasive nature of these procedures. Unlike traditional laser-based surgeries, which require the removal of corneal tissue, lens-based solutions like the EVO ICL preserve the cornea and the eye’s natural crystalline lens. This preservation is crucial for maintaining long-term eye health and vision quality. As more patients and surgeons recognize the benefits of these procedures, the demand for lens-based solutions continues to rise, driving the global shift in vision correction.
The Regulatory Clock Is Ticking for Vision Correction
Just as a clock ticks down to a significant moment, the regulatory landscape for vision correction is rapidly evolving. Expanded regulatory indications for EVO ICL in key markets have broadened the addressable patient population, making these lens-based solutions more accessible. This regulatory progress, combined with growing real-world evidence and long-term clinical outcomes, reinforces the safety and effectiveness of EVO ICLs. As the clock ticks, more patients and surgeons are turning to these advanced solutions, signaling a critical juncture in the industry.
STAAR Surgical’s EVO ICL Platform Leads the Charge
STAAR Surgical has been at the forefront of this shift, with its EVO ICL platform leading the charge. The company’s proprietary Collamer material, a biocompatible substance, supports long-term safety outcomes, making EVO ICLs a trusted choice for vision correction. The EVO family of Implantable Collamer Lenses is designed to provide durable, high-quality vision correction for a range of refractive errors through a quick, minimally invasive procedure. “As surgeons and patients seek effective and minimally invasive options that preserve corneal integrity, EVO ICL is increasingly becoming a preferred choice in markets around the world,” Andrews noted.
Future Outlook
The future of vision correction is poised to continue evolving, with lens-based solutions like EVO ICLs playing a pivotal role. As regulatory progress and clinical evidence continue to support the safety and effectiveness of these procedures, the global shift toward lens-based refractive correction is likely to accelerate. By 2025, the average ICL patient is expected to be 32 years old, highlighting the growing demand among younger populations for minimally invasive vision correction options.
Conclusion
STAAR Surgical’s milestone of 4 million ICL sales marks a significant shift in the vision correction industry, driven by the growing preference for minimally invasive, lens-based solutions. For ophthalmic professionals and patients, this milestone signals a new era in vision correction. How is your practice preparing for this shift? Join the conversation in the comments below.
About STAAR Surgical
STAAR Surgical is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material.
STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye’s natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland.
Source link: https://www.businesswire.com/
